Jefferies reiterated its Hold rating for Tesla (TSLA) and raised its price target to $400 per share from $375. The firm emphasized its increased confidence in Tesla’s Q2 EBIT, projecting $1.45 billion (5.1% margin) with outer-year EBIT growth of approximately 6%. This adjustment reflects optimism about Tesla’s operational performance and long-term positioning in the automotive and tech sectors.
JPMorgan upgraded American Express (AXP) to Overweight from Neutral, citing its defensive revenue characteristics. The firm highlighted AXP’s affluent customer base, which is less exposed to volatility driven by the Middle East crisis and energy price fluctuations. “The premium valuation is justified given the company’s resilience in a fragmented economic environment,” per the analysis.
JPMorgan initiated coverage of CardiGene (KARD) with an Overweight rating and a $51 December 2027 price target. Analysts noted the company’s robust pipeline of biotech assets, which could deliver significant near- and long-term value. “Kardan’s innovation in niche therapeutic areas positions it as a high-potential player,” stated the firm.
Morgan Stanley upgraded Keysight Technologies (KEYS) to Overweight from Equal Weight, noting the company’s strong positioning in AI infrastructure. “The expansion of AI network architectures opens new growth opportunities for Keysight,” the firm added, highlighting its role in advancing AI-driven semiconductor testing.
Jefferies upgraded Deckers (DLTR) to Buy from Hold, emphasizing upside in HOKA’s performance and lifestyle segments. “HOKA’s cross-pollination with UGG’s success could drive margin expansion as oil prices stabilize,” analysts noted. The firm also pointed to Deckers holding 13% of its market cap in cash to mitigate downside risk.
Wells Fargo initiated coverage of Atmos Energy (ATO) with an Overweight rating, calling it a compelling entry point. The firm highlighted Atmos’ low-volatility exposure to Texas infrastructure growth, noting its critical role in energy distribution and utilities.
Wells Fargo also initiated coverage of MDU Resources (MDU) as Overweight, stressing its “solid regulated growth story.” MDU has outperformed utilities year-to-date amid a shift toward cleaner business mixes and organic growth, particularly in datacenter infrastructure partnerships.
Jefferies upgraded Shopify (SHOP) to Buy from Hold, citing near-term tailwinds in agentic commerce and strong fundamentals. “The platform’s adaptability positions it favorably for long-term disruptors in retail and e-commerce ecosystems,” the analysis stated.
HSBC upgraded Capital One (CO) to Buy from Hold, arguing the stock is undervalued. “Current underperformance appears discounted amid robust deposit growth and fintech adoption,” the firm argued, highlighting its exposure to underserved credit markets.
Morgan Stanley added SpaceX to its Space 60 list, a curated portfolio of space value-chain leaders. “SpaceX’s vertical integration and scale make it a cornerstone of the sector,” the firm noted, alongside additions like HawkEye 360, Applied Aerospace, and Satellogic.
Oppenheimer reiterated Netflix (NFLX) as Perform (Overweight) but lowered its price target to $100 from $120. Despite the cut, analysts stressed Netflix’s historically low P/E ratio and resilience amid “overblown” concerns about viewership and ad monetization headwinds.
Citi upgraded Apple (AAPL) to Buy from Neutral, raising its price target to $365. The firm emphasized Apple’s leadership in devices despite slowing markets, with features like AI-driven software updates sustaining competitive differentiation.
<div class=”Goldman-Nio”:
Goldman Sachs upgraded Nio (NIO) to Buy from Neutral, projecting 46% upside to a $7.0/share DCF target. The upgrade hinges on Nio’s rapid volume growth, margin expansion, and projected free cash flow turnaround in 2026. “Nio is a growth leader in China’s EV market,” wrote Goldman analysts.
Rothschild initiated Fastenal (FAST) with a Buy rating, praising its “best-in-class operational efficiency.” The firm sees the industrial distributor as a leader in high-service distribution models, particularly as industrial automation scales.
UBS upgraded Solstice Advanced Materials (SOLS) to Buy from Neutral, calling its recent sell-off a cautionary tale for investors. “Specialty material demand remains resilient, offering upside in cyclicality,” per the note, as SOLS gains traction in green energy applications.
Truist upgraded Biogen (BIIB) to Buy from Hold, ticking bullish on Tau therapy for Alzheimer’s and Biogen’s broader pipeline. Analysts raised the price target to $235 amid de-risking of near-term clinical trial data, projecting mid-single-digit EPS growth in FY24.
KeyBanc initiated SiteOne (SITE) as Overweight, naming it an industry leader in irrigation automation. Analysts tied its $145 price target ($20 upside) to U.S. focus on infrastructure spending and smart agriculture adoption.
Needham initiated Park Aerospace (PKE) as Buy, highlighting its role as a “leading advanced composites supplier” in defense and aerospace markets. The firm views its $43 target as a strong entry point amid rising defense budgets.
Jefferies upgraded BeOne (ONC) to Buy from Hold, citing strong hematology pipelines and near-term catalysts. “ONC’s targeted therapies for blood cancers offer high-risk-adjusted returns,” the firm argued.
Piper Sandler initiated Equillium (EQ) as Overweight with a $20 PT, labeling it “severely undervalued.” The biotech “has actionable targets in autoimmune therapies,” per analysts, with early-stage trials showing promising efficacy data.
Citi initiated Bel Fuse (BEFS) as Buy with a $325 PT, citing its reinvention in niche connector markets. “The company’s consolidation of legacy businesses has stabilized margins amid defense sector recovery,” analysts noted.
Goldman Sachs initiated Praxis Precision Medicines (PRAX) as Buy, targeting $447/share. The firm emphasized PRAX’s “blockbuster pipeline candidates for rare diseases,” with early Phase 3 trials showing potential 10x revenue growth.
Goldman Sachs also initiated Stoke Therapeutics (STOK) as Buy, pledging $44/share. The firm highlighted its gene-editing platform for curing genetic disorders, with early clinical success in sickle cell trials.
Bank of America upgraded Saia (SAIA) to Buy from Neutral, projecting upside in freight rates and productivity gains from its BTSA Truck Shipper Survey. SAIA’s intercity logistics network gained traction amid supply chain restabilization trends.
Bank of America downgraded Papa John’s (PZZA) to Underperform from Neutral, citing operational volatility post-CFO departure. “Leadership instability and declining franchise investor confidence overshadow turnaround hopes,” the note warned.
Guggenheim initiated BrightSpring Health (BTSG) as Buy with an $81 PT. The home healthcare provider “benefits from aging populations and payer reimbursement reforms,” noted analysts, averaging 6% annual U.S. growth projections.
Benchmark initiated Disney (DIS) as Buy, projecting a $115 price target. “The company’s synergistic streaming/content and IP portfolio support a 17x FY26 AEPS multiple,” the firm added, citing Tale IP advancements (e.g., Avatar sequels).
Loop downgraded Best Buy (BBY) to Hold from Buy, citing overvaluation. The firm cut its price target to $82 amid “volatile retail performancer tions,” warning margins may not meet upside.
Wells Fargo upgraded Humana (HUM) to Overweight from Equal Weight, noting moderated Medicare Advantage (MA) cost trends. Analysts revised upgrade, citing improved underwriting margins and 6% enrollment growth in MA plans.
Benchmark initiated Deep Fission (DFPN) as Buy with a $20 PT, spotlighting its Small Modular Reactor (SMR) technology. “The Gravity Reactor’s pressurized water design offers 30% lower costs vs. traditional reactors,” per the analysis, with government contracts accelerating deployment.
